ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1897

Circulating T-Helper Cell- Associated Cytokines and Chemokines in Localized Scleroderma

Kathryn S. Torok1, Katherine Kurzinski2, Christina Kelsey3, Kelsey Magee4, Jonathan Yabes5, Abbe N. Vallejo6, Thomas A. Medsger Jr.7 and Carol A. Feghali-Bostwick8, 1Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 2Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 3Pediatric Rheumatology, University of Pittsburgh/UPMC, Pittsburgh, PA, 4Pediatric Rheumatology, University of Pittsburgh, Pittsburgh, PA, 5Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 6Department of Immunology, University of Pittsburgh, Pittsburgh, PA, 7Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, 8Medicine, Medical University of South Carolina, Charleston, SC

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biomarkers, cytokines, Morphea, pediatric rheumatology and scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Pathogenesis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose:
Localized scleroderma (LS) is an autoimmune disease of the skin and underlying tissues which results in disfigurement and orthopedic complications, especially when the onset is in childhood. LS has both inflammatory and fibrotic components, making it similar to systemic sclerosis (SSc), its ‘companion’ disease. Identifying potential biomarkers involved with disease propagation may lead to future therapeutic targets. T-helper (Th) cell subsets and their associated cytokines are thought to contribute to the pathogenesis of systemic sclerosis (SSc). Traditionally, a Th2 predominant response has been supported, but more recent data also implicate Th1, Th17 and various chemokine involvement. This concept in LS has only been partially investigated, with studies evaluating only a handful of cytokines associated with Th cell lineages, and not examined in reference to disease activity. This study was designed to extensively evaluate the Th-cell associated plasma cytokine and chemokine profiles of patients with pediatric LS.

Methods:
Plasma samples were obtained from 69 pediatric LS patients and 71 healthy pediatric controls. Twenty-nine cytokines and chemokines were analyzed using a Th1, Th2, and Th17 Millipore luminex panel comparing LS to healthy controls, with additional analyses predetermined to be dedicated to disease activity parameter. The modified Localized Scleroderma Severity Index (mLoSSI) and the Physician Global Assessment of Disease Activity (PGA-A) were the main parameters compared to the cytokine/chemokine levels. Mann-Whitney U test was employed to compare cytokine levels between LS and healthy groups and Spearman rank correlation was used to determine relationships between individual analytes and clinical parameters (p <0.05). Type I error due to multiple testing was controlled for using the Benjamini-Hochberg method.

Results:
The levels of the following cytokines were significantly elevated in LS patients compared with healthy controls: IP-10, MCP-1, IL-17A, IL-12p70, GM-CSF, IFN-γ, IFN-α2 and PDGF-bb. When LS patients were further divided into active (n=30) and inactive states (n=39), IP-10 was significantly elevated in the active group compared to inactive (median: 2087.3 vs. 880.5 pg/ml, respectively). IP-10 levels were also significantly correlated with the Physician Global Assessment of Disease Activity (PGA-A) score (rs = 0.450, p = 0.005) and with the modified Localized Scleroderma Severity index (mLoSSI) score (rs = 0.343, p = 0.004).

Conclusion:
SSc and LS share a similar histopathology with infiltration of lymphocytes and their associated effector cytokines in skin specimens. In the current study we demonstrated a serological presence of IP-10, MCP-1, IL-17A, IL-12p70, GM-CSF, IFN-γ and IFN-α2 in localized scleroderma, with IP-10 being highly correlated with active disease. Prior SSc studies have also found similar cytokine and chemokine profiles in the circulation, with recent literature supporting a potential role of IP-10 in SSc disease severity. These findings suggest a potential immunological link between these two clinically different diseases.


Disclosure:

K. S. Torok,
None;

K. Kurzinski,
None;

C. Kelsey,
None;

K. Magee,
None;

J. Yabes,
None;

A. N. Vallejo,
None;

T. A. Medsger Jr.,
None;

C. A. Feghali-Bostwick,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/circulating-t-helper-cell-associated-cytokines-and-chemokines-in-localized-scleroderma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology